Related Experiment Video
Updated: Feb 12, 2026

Intravitreal Injections in the Ovine Eye
Published on: July 5, 2022
[Systemic safety following intravitreal injections of anti-VEGF]
S Baillif1, B Levy2, J-F Girmens3
1Département d'ophtalmologie, hôpital Pasteur, 30, voie Romaine, 06000 Nice cedex 1, France.
Abstract:
The goal of this manuscript is to assess data suggesting that intravitreal injection of anti-vascular endothelial growth factors (anti-VEGFs) could result in systemic adverse events (AEs). The class-specific systemic AEs should be similar to those encountered in cancer trials. The most frequent AE observed in oncology, hypertension and proteinuria, should thus be the most common expected in ophthalmology, but their severity should be lower because of the much lower doses of anti-VEGFs administered intravitreally. Such AEs have not been frequently reported in ophthalmology trials. In addition, pharmacokinetic and pharmacodynamic data describing systemic diffusion of anti-VEGFs should be interpreted with caution because of significant inconsistencies reported. Thus, safety data reported in ophthalmology trials and pharmacokinetic/pharmacodynamic data provide robust evidence that systemic events after intravitreal injection are very unlikely. Additional studies are needed to explore this issue further, as much remains to be understood about local and systemic side effects of anti-VEGFs.
Insights
Intravitreal anti-vascular endothelial growth factors (anti-VEGFs) injections are unlikely to cause systemic adverse events. Safety data and pharmacokinetic studies suggest these side effects are rare in ophthalmology, despite concerns from cancer trials.
Area of Science:
- Ophthalmology
- Pharmacology
- Clinical Trials
Background:
- Intravitreal anti-vascular endothelial growth factors (anti-VEGFs) are used to treat various eye conditions.
- Concerns exist regarding potential systemic adverse events (AEs) similar to those seen in oncology.
Purpose of the Study:
- To evaluate the likelihood of systemic AEs following intravitreal anti-VEGF injections.
- To assess the consistency of pharmacokinetic and pharmacodynamic data regarding systemic drug diffusion.
Main Methods:
- Review of safety data from ophthalmology clinical trials.
- Analysis of pharmacokinetic and pharmacodynamic studies on systemic anti-VEGF distribution.
Main Results:
- Systemic AEs, such as hypertension and proteinuria, are infrequently reported in ophthalmology trials.
- Pharmacokinetic/pharmacodynamic data show inconsistencies, questioning significant systemic exposure.
- Current evidence suggests systemic events post-intravitreal injection are highly improbable.
Conclusions:
- Intravitreal anti-VEGF therapy appears safe concerning systemic adverse events.
- Further research is necessary to fully understand local and systemic effects of anti-VEGFs.
Related Concept Videos
Gas Chromatography: Sample Injection Systems
Two primary injection methods are used...
Survey Safety
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Household Wiring And Electrical Safety
Second Order systems II
First Order Systems
When a first-order system is subjected to a unit-step input, its response is characterized by its transfer function. By applying the Laplace transform of the unit-step input to the transfer function, expanding the...

